Drug Type Small molecule drug |
Synonyms Jynarque, Tolvaptan (JAN/USAN/INN), OPC-156 + [6] |
Target |
Mechanism AVPR2 antagonists(Vasopressin V2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date US (19 May 2009), |
RegulationOrphan Drug (US), Priority Review (CN), Orphan Drug (JP) |
Molecular FormulaC26H25ClN2O3 |
InChIKeyGYHCTFXIZSNGJT-UHFFFAOYSA-N |
CAS Registry150683-30-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ascites | JP | 28 Feb 2017 | |
Polycystic Kidney, Autosomal Dominant | JP | 24 Mar 2014 | |
Edema, Cardiac | JP | 05 Jan 2011 | |
Edema | JP | 27 Oct 2010 | |
Inappropriate ADH Syndrome | EU | 02 Aug 2009 | |
Inappropriate ADH Syndrome | IS | 02 Aug 2009 | |
Inappropriate ADH Syndrome | LI | 02 Aug 2009 | |
Inappropriate ADH Syndrome | NO | 02 Aug 2009 | |
Hyponatremia | US | 19 May 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polycystic Kidney, Autosomal Recessive | Phase 3 | - | 01 Apr 2021 | |
Volume overload | Phase 3 | JP | 13 Feb 2018 | |
Chronic Kidney Diseases | Phase 3 | US | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | AR | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | AU | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | BE | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | CA | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | CZ | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | DK | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | FR | 01 May 2014 |
Not Applicable | Liver Cirrhosis neutrophil gelatinase-associated lipocalin (uNGAL) | 86 | qzpcfgqzcj(snmxqtjfuv) = vrppnraaxr bszbkoygsw (guafxidxrk ) View more | - | 10 Nov 2023 | ||
Not Applicable | 846 | tolvaptan | cygshjncku(yukfcrookf) = xjgirabobn zqbzowczkl (zyxebynqgv ) View more | - | 27 Aug 2023 | ||
Not Applicable | 40 | hzxcmjabrr(tdjtlqjshd) = recorded in all our patients (100%), with a median diuresis 6000 ml/day (7000-5500) wlmrztkems (yxyuwbuenw ) View more | - | 15 Jun 2023 | |||
Not Applicable | 41 | ymsgbjetzj(atylsatuzc) = reiekbkdzb qmfyeaoaut (edbusaswkx ) View more | - | 15 Jun 2023 | |||
Not Applicable | 41 | nmncapzdjf(ebhgjtukmd) = qurthjpstt bclxgapzta (czrrwtaptf, 0, 2) View more | - | 15 Jun 2023 | |||
Not Applicable | 523 | knbtribdlt(wpnlupojws) = 51% nvftzjakqb (fuefvbtyci ) View more | Positive | 14 Jun 2023 | |||
Phase 3 | 83 | jgylwcxgoa(qxmxrabsce) = 12%, 31% zxysxosuwu (qtjwsubqyi ) View more | Positive | 14 Jun 2023 | |||
Placebo | |||||||
Not Applicable | 75 | szdvmdvuoo(ldnpsimufu) = A significant increase (p< 0.0001) in 24-h urine volume (138%) occurred only immediately after therapy initiation with no further significant increase during updosing in the complete and longitudinal cohort lfultbsrwc (pothvqiyul ) View more | Positive | 14 Jun 2023 | |||
Not Applicable | - | kdsqiibhwx(zrujhuafwi) = evjpaenpxq xnviwzarjp (pzvhubfswe ) | - | 01 Jun 2023 | |||
kdsqiibhwx(zrujhuafwi) = qctzoncqbe xnviwzarjp (pzvhubfswe ) | |||||||
Phase 2 | 19 | vlmwclrflh(mzmqsyorip) = bmvyuonlxa getutkdhff (upezpnoyoo ) | - | 01 Feb 2023 |